Bioversys Reports Key Financials & Highlights for H1 2025
BioVersys has set a 2025 start for a global Phase 3 program of BV100 in ventilator- and hospital-acquired bacterial...
Nanonewron’s Alzheimer’s Program Awarded $2.5M NIH Grant
NanoNewron has secured a $2.5 million NIH STTR Phase 2 grant to advance NN-840, a blood–brain barrier–penetrant TNF-alpha inhibitor...
Bioversys Reports Corporate Highlights, H1 2025 Financials
BioVersys has tightened its execution across three antibacterial programs while shoring up its balance sheet. The company aligned with...
Maze Therapeutics Appoints New Chief Financial Officer
Maze Therapeutics has appointed Misbah Tahir as chief financial officer, adding a capital markets veteran ahead of a dense...
BioNTx Summit Spotlights 2025’s Rising Healthcare Stars
BioNTX has named eight companies to its 2025 Rising Stars cohort, to be showcased at the 11th iC³ Life...
Nobel Laureate Dr. Ardem Patapoutian Joins Stratus Board
Stratus Therapeutics has added Nobel laureate Ardem Patapoutian to its Scientific Advisory Board as it advances ST-101, an allogeneic,...
Merakris Therapeutics Highlights Successful MTX-001 Growth
Merakris Therapeutics has enrolled the 30th patient in its Expanded Access Program for MTX-001, an injectable, cell-free amniotic fluid–derived...
IC³ Summit Reveals The Truth About Volatile Federal Funding
BioNTX’s IC³ Life Science & Healthcare Innovation Summit will put federal and alternative R&D capital under the microscope in...
Rapafusyn Closes $44M Series A for Molecular Glue Platform
Rapafusyn Pharmaceuticals has closed an oversubscribed Series A round totaling $44 million, adding BioTrack Capital and Yonjin Capital to...
Syndax Announces New Inducement Grants Under Nasdaq Listing
Syndax Pharmaceuticals has granted inducement stock options covering 167,400 shares to 11 new employees under its 2023 inducement plan,...